The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme Journal Article
| Authors: | Bambury, R. M.; Morris, P. G. |
| Article Title: | The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme |
| Abstract: | Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor with ≤10% patients surviving 5 years from the time of diagnosis. After tumor progression on frontline therapy with concomitant chemoradiotherapy followed by consolidation temozolomide there are few effective treatment options. Bevacizumab and nitrosureas are the most commonly used systemic options in this instance but no overall survival benefit has been demonstrated. In this review we outline the major avenues of research for treatment of recurrent GBM including anti-angiogenic, signaling pathway blockade and immunotherapy approaches. Results of recent trials as well as pertinent ongoing studies are discussed. Enrollment of patients to clinical trials as well as incorporation of correlative translational science studies to identify predictive biomarkers of treatment response will be key to improving outcomes in this devastating disease. © 2014 Informa UK, Ltd. |
| Keywords: | signal transduction; treatment response; unclassified drug; overall survival; genetics; drug tolerability; review; cancer recurrence; angiogenesis inhibitor; bevacizumab; erlotinib; fluorouracil; raf protein; sunitinib; cancer combination chemotherapy; drug efficacy; drug safety; hypertension; monotherapy; nonhuman; treatment duration; alpha interferon; temozolomide; outcome assessment; antineoplastic agent; cancer incidence; cancer grading; biological marker; unindexed drug; cancer immunotherapy; progression free survival; bleeding; lung non small cell cancer; epidermal growth factor receptor; practice guideline; cetuximab; cancer research; carmustine; lomustine; carcinogenesis; health care quality; immunotherapy; epigenetics; thromboembolism; glioblastoma; mammalian target of rapamycin; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; blood brain barrier; gefitinib; vasculotropin a; pazopanib; brain metastasis; oncolytic virotherapy; targeted therapy; stereotactic treatment; egfr gene; electromagnetic field; retinoblastoma protein; everolimus; brain hemorrhage; proteinuria; rapamycin; pik3ca gene; brain surgery; cilengitide; molecularly targeted therapy; pten gene; antiangiogenic; cancer prognosis; tivozanib; pik3r1 gene; ramucirumab; buparlisib; human; oncolytic parvovirus; rindopepimut; trebananib; vb 111; tumor treating fields therapy; vegfa gene |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 14 |
| Issue: | 8 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2014-08-01 |
| Start Page: | 955 |
| End Page: | 964 |
| Language: | English |
| DOI: | 10.1586/14737140.2014.916214 |
| PROVIDER: | scopus |
| PUBMED: | 24814143 |
| DOI/URL: | |
| Notes: | Export Date: 2 September 2014 -- CODEN: ERATB -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work